Lv1
60 积分 2025-05-16 加入
First-Line Immunotherapy for Non-Small-Cell Lung Cancer
1个月前
已完结
Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies
1个月前
已完结
Safety and efficacy of QL1706 plus carboplatin/etoposide (EC) as first-line (1L) treatment for extensive-stage small-cell lung cancer (ES-SCLC): The results from a phase II single-arm study
1个月前
已完结
Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817
1个月前
已完结
Non-small-cell lung cancer
2个月前
已完结
Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions
4个月前
已完结
Clinicopathologic Features of Advanced Squamous NSCLC
4个月前
已完结
Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions
4个月前
已完结
SMARCA4: Current status and future perspectives in non-small-cell lung cancer
4个月前
已完结
Cancer immunotherapy: Pros, cons and beyond
6个月前
已完结
皖公网安备34019202002308
